Skip to main content

Table 2 The pharmacological effect of QBD in clinical trials

From: Potential therapeutic effect of Qingwen Baidu Decoction against Corona Virus Disease 2019: a mini review

Disease Gender (M/F) Age (years) (range, mean) Interventions Course Clinical efficiency Reported indicators in QBD group References
Sepsis E: 11/7
C: 12/8
E: 53.27 ± 9.24
C: 51.00 ± 11.29
E: Conventional therapy + QBD (100 ml/time, tid.)
C: Conventional therapy
7 days E: 83.33%
C:75.00%
IgG↓, IgA↓, IgM↓, C3↓, CRP↑, TNF-α↓, APACHEII score↓, TCM symptom score↓ Zhang et al. [51]
Sepsis E: 18
C: 20
NR E: Conventional therapy + QBD (100 ml/time, tid.)
C: Conventional therapy
7 days E: 83.33%
C: 75.00%
TCM symptom score↓, APACHEII score↓, IgG↓, IgA↓, IgM↓, C3↓, CRP↑, TNF-α↓ Leng et al. [18]
Sepsis E: 11/7
C: 12/8
E: 53.27 ± 9.24
C: 51.00 ± 11.29
E: Conventional therapy + QBD (200 ml/time, tid.)
C: Conventional therapy
7 days E: 83.30%
C: 75.00%
TCM symptom score↓, APACHEII score↓, mortality rate↓, PT↓, APTT↓, TT↓, PLT↑ Fu et al. [54]
Sepsis E: 15/10
C: 16/8
E: 53.27 ± 9.20
C: 51.00 ± 11.29
E: Conventional therapy + QBD (100 ml/time, tid.)
C: Conventional therapy
7 days E: 84.00%
C: 75.00%
TCM symptom score↓, APACHEII score↓, IgG↓, IgA↓, IgM↓, C3↓, CRP↑, TNF-α↓ Leng et al. [52]
Sepsis E: 19/23
C: 22/20
E: 50–74, 61 ± 8.6
C: 52–75, 63 ± 7.3
E: Antibiotic therapy + QBD (100 ml/time, bid.)
C: Antibiotic therapy
7 days E: 80.95%
C: 64.28%
APACHEII score↓, IgG, ↓ IgA↓, IgM↓, C3↓, CRP↑, TNF-α↓ Chen [17]
AKI with sepsis E: 28/29
C: 30/26
E: 68.10 ± 9.07
C: 69.49 ± 8.37
E: Conventional therapy + QBD (200 ml/day, bid.)
C: Conventional therapy
7 days NR APACHEII score↓, Scr↓, BUN↓, CRP↓, TNF-α↓, IL-1β↓, IL-6↓, IL-10↓ Ge et al. 2014 [37]
Pathogen-invading-lung syndrome with sepsis E: 15/9
C: 13/11
E: 68.10 ± 9.07
C: 69.49 ± 8.37
E: Conventional therapy + QBD (100 ml/time, bid.)
C: Conventional therapy
7 days E: 95.83%
C: 83.33%
APACHEII score↓, CRP↓, WBC↓, TCM symptom score↓, blood glucose↑, antipyretic time↓ Xi et al. [20]
Sepsis with heat poisoning syndrome E: 35/24
C: 37/21
E: 46–68, 50.4 ± 8.5
C: 44–70, 51.8 ± 7.9
E: Conventional therapy + Xuebijing injection (100 mg/time, bid.) + QBD (200 mg/time, bid.)
C: Conventional therapy
7 days E: 77.97%
C: 42.37%
APACHEII↓, SOFA score↓, TNF-α↓, IL-1β↓, IL-6↓, IL-10↑, d-lactic acid↓, endotoxin↓, PCT↓, whole blood viscosity↓, plasma viscosity↓, erythrocyte deformation index↓, erythrocyte aggregation index↓, PT↑, APTT↓, TT↑, FIB↓, D–D↓, PLT↓ Ren et al. [14]
Coagulation dysfunction in sepsis E: 20/13
C: 19/12
E: 28–78, 60.94 ± 12.13
C: 28–79, 61.45 ± 12.91
E: Conventional therapy + QBD (100 ml/day, bid.)
C: Conventional therapy
7 days E: 93.90%
C: 74.20%
PLT↑, PT↓, APTT↓, Fib↓, D–D↓, TCM symptom score↓, APACHEII score↓, SOFA score↓ Gao et al. [19]
Influenza A (H1N1) with respiratory distress syndrome 2/11 12–61, 29.4 ± 14.1 Conventional therapy + QBD 7–48 days 92.31% 11 cases were cured, 1 case was effective and 1 case was ineffective Chu et al. [40]
Viral pneumonia caused by influenza A virus subtype H1N1 E: 28/22
C: 24/16
E: 40.67 ± 2.09
C: 41.68 ± 4.68
E: Conventional therapy + QBD (200 ml/day, tid.) + Tanreqing injection (30 ml/day, qd.)
C: Conventional therapy
7 days E: 96.00%
C: 70.00%
TNF-α↓, IL-6↓, IL-8↓, IL-10↑, CRP↓, TCM symptom score↓ Tian et al. [15]
SARS 4/6 15–70, 43.77 ± 12.68 Conventional therapy + QBD (150 ml/time, bid.) 5 days NR Antipyretic time↓, temperature gradually drops to normal level Zhang et al. [45]
EV 71 E: 22/8
C: 21/9
E: 2.0 ± 1.3
C: 2.1 ± 0.25
E: Conventional therapy + QBD (50 ml/time, bid. ~ tid.)
C: Conventional therapy
3–5 days E: 93.33%
C: 63.40%
Antipyretic time↓, hospital stay↓ Zhan et al. [43]
Epidemic encephalitis type B 10/6 1–11, 5.3 QBD (tid.) NR 87.50% 10 cases were cured, 4 cases were improved and 2 cases were ineffective. Yang [33]
Pneumonia E: 30
C: 30
(36/24)
E: 20–70, 53.11 ± 10.58
C: 18–67, 49.00 ± 10.61
E: Levofloxacin + QBD (150 ml/time, bid.)
C: Levofloxacin (0.5 g, qd.)
7 days E: 96.67%
C: 86.67%
Antipyretic time↓, WBC↓, NG↓ Nie et al. [66]
Mycoplasma pneumonia E: 20/25
C: 22/23
E: 9–58, 27
C: 10–63, 25
E: Azithromycin (10 mg/kg/day, i.v.) + QBD + Canopy bulk
C: Azithromycin (10 mg/kg/day, i.v.)
4 W E: 100.00%
C: 86.67%
Blood routine was normal, clinical symptoms disappeared, chest X-ray improved Shu [67]
Infant pneumonia E: 22/20
C: 23/20
E: 0.58–9
C: 0.58–8
E: Conventional therapy + QBD (3–5 ml/kg, bid.)
C: Conventional therapy
5 days E: 97.62%
C: 81.40%
NR Yao et al. [30]
Epidemic hemorrhagic fever E: 84/36
C: 40/20
E: 10–17 (13 cases); 18–49 (82 cases), 50–70 (25 cases)
C: 10–17 (4 cases); 18–49 (47 cases), 50–70 (9 cases)
E: Ribavirin (15 mg/kg, qd.) + QBD (bid.)
C: Ribavirin (15 mg/kg, qd.)
NR NR Days of fever↓, polyuria↓, platelet recovery↓, urine protein turning negative↓, the rate of oliguria and hypotension shock↑, adverse reactions ↓ Hao et al. [27]
Hyperthermia E: 14/12
C: 11/15
E: 18–62
C: 19–63
E: QBD (150 ml/time, bid.)
C: Angong Niuhuang Pill (1 pill, qd ~ bid.)
NR E: 92.30%
C: 57.69%
NR Wang et al. [55]
Hemorrhagic fever with renal syndrome E: 45
C: 45
(51/39)
24–48 E: Conventional therapy + QBD (bid.)
C: Conventional therapy
7 days NR CD4+↑, CD8+↓,
CD4+/CD8+
Li et al. [26]
Infectious mononucleosis E: 46
C: 45
(43/48)
0.83–6 E: Ganciclovir (10 mg/kg d, bid.) + QBD (bid. ~ tid.)
C: Ganciclovir (10 mg/kg d, bid.)
7 days E: 93.48%
C: 80.00%
NR Dong [41]
Infectious mononucleosis in children E: 11/9
C: 12/8
E: 2–13
C: 3–12
E: ganciclovir (5 mg/kg) + QBD (200 ml/time, qid.)
C: ganciclovir (5 mg/kg)
7–14 days E: 95.00%
C: 80.00%
Duration of main clinical manifestations↓, WBC↓, heterotypic lymphocyte↓, liver function indices↓ Sheng et al. [42]
Epidemic cerebrospinal meningitis 40/22 8–40, 18 QBD (tid.) 15 days 98.39% NR Sun et al. [29]
Hand-foot-and-mouth disease E: 30/20
C: 25/25
E: 1–3 (37 cases), 4–5 (13 cases)
C: 1–3 (36 cases), 4–5 (14 cases)
E: Ribavirin (10–15 ml/kg, qd.) + QBD (100–150 ml/day, tid. ~ qid.)
C: Ribavirin (10–15 ml/kg, qd.)
10 days E: 94.00%
C: 88.00%
Antipyretic time↓, disappearance time of oral herpes↓, severe conversion rate↓ Xu et al. [68]
Erythroderma psoriasis E: 14/15
C: 16/13
E: 20–63, 46.35 ± 2.16
C: 20–64, 47.32 ± 2.61
E: QBD (200 ml/time, tid.)
C: Acitretin capsules (20 mg/kg)
3 M E: 96.55%
C: 75.86%
Adverse reactions ↓ Li [69]
  1. E experimental group, C control group, W week, APACHE acute physiology and chronic health evaluation, M month(s), WBC white blood cell, EV enterovirus, SOFA sequential organ failure assessment, NG neutrophil granulocyte, CRP C-reactive protein, PLT platelet count, PT prothrombin time, APTT activated partial thromboplastin time, TT thrombin time, Fib fibrinogen, D-D D-Dimer, AKI acute kidney injury, BUN blood urea nitrogen, NR not report